A Safety and Efficacy Study of FCR001 vs Standard of Care in de Novo Living Donor Kidney Transplantation

Summary

A randomized controlled study to evaluate the safety, efficacy, and overall benefit of FCR001 cell therapy in de novo living donor renal transplantation.

Timeline

Start

2019-10-25

Primary completion

2023-02-16

Completion

2023-02-16

Outcome

Outcome not reported

Stopped: “Talaris decided to discontinue living donor kidney transplant development program”

Drugs

Indications